-
1 Comment
H.U. Group Holdings, Inc is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
H.U. Group Holdings, Inc's total revenue rose by 29.3% to $63B since the same quarter in the previous year.
Its net income has increased by 1206.7% to $8B since the same quarter in the previous year.
Finally, its free cash flow grew by 783.5% to $8B since the same quarter in the previous year.
Based on the above factors, H.U. Group Holdings, Inc gets an overall score of 4/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3822000000 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Beta | 0.32 |
|---|---|
| PE Ratio | None |
| Market Cap | 156B |
| Target Price | 2327.5 |
| Dividend Yield | 4.6% |
H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment collects specimens from medical offices, clinics, and hospitals, and conducts various tests at its laboratories. The segment also provides precision of the tests, pre-trial setup work, specimen collection and transport, measuring, result reports, and data management services for support in research and development of medicine. The In Vitro Diagnostics segment is involved in the provision of cerebrospinal fluid reagent, compatible with its automated chemiluminescent enzyme immunoassay system; development of blood-based reagents, as well as biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. This segment also supplies key raw materials to global in-vitro diagnostics companies through a CDMO business model; offers Lumipulse, an automated chemiluminescence enzyme immunoassay system that offers reagents; and rapid diagnostics kits that serves as a platform for testing infectious diseases such as influenza and COVID-19. The Healthcare-related Services segment provides in-house sterilization services at the central supply rooms in hospitals and external sterilization at the sterilization centers; and offers operating and endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services. This segment also engages in the sale of medical equipment, supplies, and consumables related to central supply and operating rooms; provision of home medical care and nursing services; and rental of nursing care equipment, such as wheelchairs and nursing beds. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4544.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
